Sure do Pete..
1. MSB has product approval, Pluristem does not.
2. The risk of Phase 2 is much much higher than Phase 3 trials, and I seem to recall this Israeli company has been placed on clinical hold once before.
3. Lonza's Singaporean site has been inspected, and approved, by every major regulatory agency. She is suggesting that a site that is doing a Phase 2 process (which the FDA has never inspected or looked at its' quality systems) is better than Lonza's? I don't quite get it.
I detect a whiff of self-interest but I may of course be wrong.
Sure do Pete.. 1. MSB has product approval, Pluristem does not....
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.5¢ |
Change
0.005(0.54%) |
Mkt cap ! $1.056B | |||
| Open | High | Low | Value | Volume |
| 93.0¢ | 93.5¢ | 91.5¢ | $1.473M | 1.596M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 32370 | 92.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 93.0¢ | 60258 | 5 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |